A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on Aging published on June 5, 2025, in Science has stated that the impact of taurine supplementation at delaying aging or treating aging-related conditions is context-dependent, and that the circulating levels of taurine are impacted by factors unique to each individual rather than declining with age. To qualify taurine as a true marker of aging, it should change with age across diverse populations over time and ideally supported by longitudinal data. Read More
Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which emerged with an oversubscribed $15 million initial financing to advance three platforms with broad potential across therapeutic areas. Read More
Casma Therapeutics Inc. has nominated its first development candidate, CSM-101, a first-in-class TRPML1 agonist. CSM-101 is being developed for the treatment of Gaucher’s disease patients with Parkinson’s disease, with the potential to expand into GBA-associated Parkinson’s disease and broader Parkinson’s disease populations. Read More
Aqilion AB has released promising results from new studies with molecules from the company’s lead series within the TAK1 program, demonstrating a strong disease-modifying effect in a well-established model of skin inflammation. Read More
Using agonists to desensitize the homotetrameric transient receptor potential ankyrin 1 (TRPA1) channel is a validated strategy for pain relief. Read More
Immunoprecise Antibodies Ltd. has discovered a highly conserved epitope across all four dengue virus serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) using its proprietary Lensai platform powered by its Hyft technology. Read More
Biogen Inc. has disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of stroke, psoriasis, arthritis, pain, silicosis, alopecia and more. Read More
Solvonis Therapeutics plc has completed synthesis of development candidates for its SVN-SDN-014 program, a novel series of serotonin, dopamine and noradrenaline modulators. Read More
Scientists at Shanghai Tech University have used the scaffold-hopping artificial intelligence model Geminimol to identify N-methyl-D-aspartate (NMDA) receptor ligands that show selectivity and specificity. The researchers found that GM-10 could be a potent inhibitor of the GluN1/GluN3A subunits of the NMDA receptor, demonstrating the utility of this technique to develop new drugs.
Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors reported to be useful for the treatment of herpes virus infection. Read More
Merck Sharp & Dohme LLC has identified compounds acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and/or 2 (HCN2) blockers reported to be useful for the treatment of neuropathic pain, tinnitus, psychiatric and neurological disorders. Read More
Seyltx Inc. has entered into an option agreement with Neurop Inc. for a portfolio of novel GluN2B antagonists. The compounds include NP-10679, which has completed phase I, and seven preclinical candidates. Read More
Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic steatosis, liver inflammation, hepatitis C virus (HCV) infection and liver cancer (hepatocellular carcinoma). Read More
The EMA’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending European orphan drug designation for Hemispherian AS’s GLIX-1 for the treatment of glioma. Read More
Mindimmune Therapeutics Inc. has been awarded a grant by Rhode Island Life Science Hub to accelerate preclinical development work on MITI-101 for the treatment of mild to moderate Alzheimer’s disease. The award will accelerate development work needed to start first-in-human studies. Read More
Vertex Pharmaceuticals Inc. has described polycystin-1 (PKD1) (mutant) correctors reported to be useful for the treatment of autosomal dominant polycystic kidney disease. Read More
